TWI291957B - Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same - Google Patents
Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same Download PDFInfo
- Publication number
- TWI291957B TWI291957B TW091102310A TW91102310A TWI291957B TW I291957 B TWI291957 B TW I291957B TW 091102310 A TW091102310 A TW 091102310A TW 91102310 A TW91102310 A TW 91102310A TW I291957 B TWI291957 B TW I291957B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- same
- carbon atoms
- formula
- chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Description
蔻0808
(R3)p 、申請專利範圍 n、P、q及r爲0、1或2之整數〕〇 2. 種以通式(Ϊ )所表不之化合物或其藥學上能容 許之鹽類之製造方法,其特徵爲,係使得以通式(π ): (H) 〔式中,A丨、A?、I及p與上述相同、X爲鹵素等之 脫離基或旋光性的磺內醯胺衍生物〕所表示之化合物,與 以通式(羾): 、 (m) (請先閲讀背面之注意事項再填寫本頁) 、τ ·· 線 (式中A3、A4、R3及η、q、r與上述相同)所表示 之化合物’於鹼存在下加熱回流來進行史陶丁格 (Stuadinger)反應或曼尼希(Mannich)反應。 3. —種以通式(I )所表示之化合物或其藥學上能容 許之鹽類之製造方法,其特徵爲,係使得以通式(IV):
本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) A8B8C8D8
X 申請專利範圍 之化合物,與以通式(V): ·Α2、 (V) (式中,Α】、Α2、ρ、X及R3與上述相同)所表示之 化合物於鹼存在下反應。 4. 一種以通式(I )所表示之化合物或其藥學上能容 許之鹽類之製造方法,其特徵爲,係使得以通式(VI): (R3)q (VI) (請先閲讀背面之注意事項再填寫本頁)
(R3), •1T: 〔式中,η、p、q、r、Ai、A2、A3、A4 及 R3 與上述 相同’ Y爲旋光性的磺內醯胺衍生物〕所表示之化合物在 氫氧化鋰等鹼存在下反應來去除旋光性的磺內醯胺衍生物 成爲以通式(VI-1):
A 必 A2r^(R3)q 0¾¾ …… ^ A4 (R3)r 〔式中,η、p、q、r、Αι、A2 ' A3 ' A4 以及 R3 與上述 相同〕所表示之化合物,之後, a)於無溶劑或二氯甲烷、二氯乙烷等之溶劑中、鹵化 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公爱) A8BSC8D8 申請專利範圍 劑存在下反應; b) 於縮合劑與二氯甲烷、DMF (N,N—二甲基甲醯胺) 等之溶劑中,鹼存在下反應; c) 於BihP(第三丁基膦)、Ph3P(三苯基膦)之存在下’使 光延試劑反應; d) 於BiuP(第三丁基膦)、PbP(三苯基膦)之存在下’使 (PyS) 2反應;或是, e) 於2,6—二氯化苯甲醯氯、2,4,6—三氯化苯甲醯氯等 反應在NaH存在下反應,然後以氫氧化鈉水溶液處理; 來進行通式(VI-1)所表示之化合物之環化反應。 5. —種以通式(I )所表示之化合物或其藥學上能容 許之鹽類之製造方法,其特徵爲,係使得以通式(VI): •CR3)« (請先閲讀背面之注意事項再填寫本頁) (VI)
,^γ·α4 (R3)r 線 〔式中,η、p、q、r、Αι、A2、A3、八4、R3 以及 γ 與 上述相同〕所表示之化合物在氫氧化鋰等鹼存在下反應$ 去除旋光性的磺內醯胺衍生物成爲以通式(VI-1): 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) A8 B8 C8 D8 六、申請專利範圍
〔式中,n、p、q、r、Αι、Ας、A3、At 以及 Rj 與上述 相同〕所表示之化合物之後’進行酯化成爲以通式(VI-2):
〔式中,η、p、q、r、Αι ' A2、A3、A4 以及 R3 與上述 相同,R7係甲基或乙基〕所表示之化合物,之後, a) 與LDA (二異丙醯胺鋰)或是LiHMDS〔雙(三甲 基甲矽烷基)醯胺鋰〕等鹼在溶劑中反應;或是 b) 與EtMgBr(溴化乙基鎂)、t-BuMgBr(溴化正丁基鎂) 等之格利雅試劑反應, 來進行通式(VI-2)所表示之化合物之環化反應。 6. —種以通式(VII)所表示之化合物或其藥學上能容 許之鹽類的製造方法, (請先閲讀背面之注意事項再塡寫本頁) 線 本纸張夂度適用中國國家標準(CNS)A4規格(210 X 297公楚·) 申請專利範圍 A8 B8 C8 D8
式中,A]、A〗、八4、R_3、η、p、q及r與上述相同;R? 爲單鍵(一)、_CH=HC—或一 OCH2 ; k'爲0或1〜9的整數 〕所表示之化合物或其藥學上能容許之鹽類;其特徵在於 ,係使得以通式(VEI) 7
A
(vm) 〔式中,Αι、A2、A4、R3、η、p、q及R3與上述相同 ;Z爲鹵素原子或三氟甲磺酸基等之脫離基,k'爲0或1〜 10的整數〕所表示之化合物,與以通式(IX ): R3y^R3 1^6-(012卜0人112 (式中,112及R3與上述相同,R6爲鹵素原子、一 CH CH2或-CH2〇H)所表示之化合物,在醋酸鈀以及2_ ( 三級丁基膦基)聯苯存在下進行偶合反應。 (IX) (請先閲讀背面之注意事項再塡寫本頁) 線 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) A8B8C8D8 六、申請專利範圍 7. —種降血清膽固醇組成物,係含有以通式(I )所 表示之化合物或其藥學上能容許之鹽類。 8. 如申請專利範圍第7項之降血清膽固醇組成物,係 進一步倂用/5 -內酿胺酶抑制劑。 (請先閲讀背面之注意事項再填寫本頁)
-P 、\έ 線 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001048202 | 2001-02-23 | ||
JP2001128031 | 2001-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI291957B true TWI291957B (en) | 2008-01-01 |
Family
ID=26609978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW091102310A TWI291957B (en) | 2001-02-23 | 2002-02-08 | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
Country Status (18)
Country | Link |
---|---|
US (1) | US7045515B2 (zh) |
EP (1) | EP1362855B1 (zh) |
JP (1) | JP4229701B2 (zh) |
KR (1) | KR100721639B1 (zh) |
CN (1) | CN1273467C (zh) |
AT (1) | ATE374769T1 (zh) |
AU (1) | AU2002237522B2 (zh) |
BR (1) | BRPI0206193B1 (zh) |
CA (1) | CA2438961C (zh) |
DE (1) | DE60222742T2 (zh) |
DK (1) | DK1362855T3 (zh) |
ES (1) | ES2294101T3 (zh) |
HK (1) | HK1060357A1 (zh) |
MX (1) | MXPA03005073A (zh) |
PT (1) | PT1362855E (zh) |
RU (1) | RU2301799C2 (zh) |
TW (1) | TWI291957B (zh) |
WO (1) | WO2002066464A1 (zh) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002079174A2 (en) | 2001-03-28 | 2002-10-10 | Schering Corporation | Enantioselective synthesis of azetidinone intermediate compounds |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
JP2005015434A (ja) * | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
CA2543943A1 (en) * | 2003-10-30 | 2005-05-19 | Merck & Co., Inc. | 2-azetidinones as anti-hypercholesterolemic agents |
EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
PL1682499T3 (pl) * | 2003-11-10 | 2008-01-31 | Microbia Inc | 4-Biarylilo-1-fenyloazetydyn-2-ony |
EP1832576A1 (en) * | 2003-11-10 | 2007-09-12 | Microbia Inc. | 4-Biarylyl-1-phenolyzetidin-2-ones |
JP4688819B2 (ja) | 2003-12-23 | 2011-05-25 | アストラゼネカ アクチボラグ | コレステロール吸収阻害活性を有するジフェニルアゼチジノン誘導体 |
CA2550373C (en) | 2003-12-23 | 2012-01-31 | Merck & Co., Inc. | Anti-hypercholesterolemic compounds |
MXPA06013456A (es) | 2004-05-21 | 2007-03-01 | Sanofi Aventis Deutschland | Metodo para producir derivados de 1,4-difenilazetidinona. |
CA2581596A1 (en) * | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinations of substituted azetidonones and cb1 antagonists |
SG163577A1 (en) | 2004-12-03 | 2010-08-30 | Schering Corp | Substituted piperazines as cb1 antagonists |
TW200726746A (en) * | 2005-05-06 | 2007-07-16 | Microbia Inc | Processes for production of 4-biphenylylazetidin-2-ones |
JP2008540557A (ja) * | 2005-05-11 | 2008-11-20 | マイクロビア インコーポレーテッド | フェノール型4−ビフェニリルアゼチジン−2−オンの製造方法 |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
KR20080025077A (ko) * | 2005-05-25 | 2008-03-19 | 마이크로비아 인코포레이티드 | 4-(비페닐일)아제티딘-2-온 포스폰산의 제조방법 |
EP1893222A4 (en) * | 2005-06-15 | 2010-07-07 | Merck Sharp & Dohme | ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS |
UY29607A1 (es) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
US7635705B2 (en) | 2005-06-20 | 2009-12-22 | Schering Corporation | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists |
AR057072A1 (es) | 2005-06-22 | 2007-11-14 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
NZ566877A (en) | 2005-09-29 | 2010-05-28 | Sanofi Aventis | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
TW200806623A (en) * | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
RU2008133381A (ru) * | 2006-01-18 | 2010-02-27 | Шеринг Корпорейшн (US) | Модуляторы каннабиноидного рецептора |
JP4880348B2 (ja) * | 2006-04-25 | 2012-02-22 | 壽製薬株式会社 | アズレン誘導体及びそれを有効成分とする血清コレステロール低下剤 |
AR060623A1 (es) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
CA2663434A1 (en) * | 2006-09-15 | 2008-03-20 | Schering Corporation | Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders |
MX2009002922A (es) | 2006-09-15 | 2009-04-01 | Schering Corp | Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico. |
JP2010503675A (ja) | 2006-09-15 | 2010-02-04 | シェーリング コーポレイション | 疼痛、糖尿病および脂質代謝の障害の治療に有用なスピロ縮合アゼチジン誘導体 |
CA2663502A1 (en) * | 2006-09-15 | 2008-03-20 | Schering Corporation | Azetidinone derivatives and methods of use thereof |
WO2008085300A1 (en) * | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Anti-hypercholesterolemic compounds |
DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2008130616A2 (en) * | 2007-04-19 | 2008-10-30 | Schering Corporation | Diaryl morpholines as cb1 modulators |
RU2010102478A (ru) * | 2007-06-28 | 2011-08-10 | Интэрвэт Интэрнэшнл Б.Ф. (NL) | Замещенные пиперазины как антагонисты св1 |
EP2170847A2 (en) * | 2007-06-28 | 2010-04-07 | Intervet International BV | Substituted piperazines as cb1 antagonists |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
AR072707A1 (es) | 2008-07-09 | 2010-09-15 | Sanofi Aventis | Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
EP2403848A1 (en) | 2009-03-06 | 2012-01-11 | Lipideon Biotechnology AG | Pharmaceutical hypocholesterolemic compositions |
CN101993403B (zh) * | 2009-08-11 | 2012-07-11 | 浙江海正药业股份有限公司 | 氮杂环丁酮类化合物及医药应用 |
RU2012111354A (ru) | 2009-08-26 | 2013-10-10 | Санофи | Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
CN104860980B (zh) * | 2015-04-23 | 2018-06-19 | 上海弈柯莱生物医药科技有限公司 | 一种用于合成依折麦布的中间体及其制备方法和应用 |
CN113825839A (zh) | 2019-03-20 | 2021-12-21 | 雷杰纳荣制药公司 | 用固醇调节元件结合蛋白切割激活蛋白(scap)抑制剂治疗脂质水平升高 |
WO2020191141A1 (en) | 2019-03-20 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5857360A (ja) * | 1981-10-01 | 1983-04-05 | Ajinomoto Co Inc | アゼチジノン誘導体 |
HUT67341A (en) | 1991-07-23 | 1995-03-28 | Schering Corp | Substituted beta-lactam compounds useful as hypocholesterolemic agents, pharmaceutical compositions containing the same and process for the production thereof |
US5412092A (en) * | 1993-04-23 | 1995-05-02 | Bristol-Myers Squibb Company | N-substituted 2-azetidinones |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
NZ321766A (en) * | 1995-10-31 | 1999-07-29 | Schering Corp | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
WO1997016424A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
CN1221546C (zh) * | 2000-12-21 | 2005-10-05 | 阿文蒂斯药物德国有限公司 | 二苯基氮杂环丁酮衍生物、它们的制备方法、含有这些化合物的药物和它们的用途 |
-
2002
- 2002-02-08 TW TW091102310A patent/TWI291957B/zh not_active IP Right Cessation
- 2002-02-20 DK DK02703861T patent/DK1362855T3/da active
- 2002-02-20 KR KR1020037010927A patent/KR100721639B1/ko not_active IP Right Cessation
- 2002-02-20 MX MXPA03005073A patent/MXPA03005073A/es active IP Right Grant
- 2002-02-20 RU RU2003128424/04A patent/RU2301799C2/ru not_active IP Right Cessation
- 2002-02-20 PT PT02703861T patent/PT1362855E/pt unknown
- 2002-02-20 AU AU2002237522A patent/AU2002237522B2/en not_active Ceased
- 2002-02-20 EP EP02703861A patent/EP1362855B1/en not_active Expired - Lifetime
- 2002-02-20 CA CA2438961A patent/CA2438961C/en not_active Expired - Fee Related
- 2002-02-20 BR BRPI0206193A patent/BRPI0206193B1/pt not_active IP Right Cessation
- 2002-02-20 ES ES02703861T patent/ES2294101T3/es not_active Expired - Lifetime
- 2002-02-20 DE DE60222742T patent/DE60222742T2/de not_active Expired - Lifetime
- 2002-02-20 JP JP2002565979A patent/JP4229701B2/ja not_active Expired - Lifetime
- 2002-02-20 CN CNB028052013A patent/CN1273467C/zh not_active Expired - Fee Related
- 2002-02-20 WO PCT/JP2002/001481 patent/WO2002066464A1/ja active IP Right Grant
- 2002-02-20 US US10/450,171 patent/US7045515B2/en not_active Expired - Lifetime
- 2002-02-20 AT AT02703861T patent/ATE374769T1/de active
-
2004
- 2004-05-12 HK HK04103348A patent/HK1060357A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2438961A1 (en) | 2002-08-29 |
AU2002237522B2 (en) | 2007-08-02 |
EP1362855A1 (en) | 2003-11-19 |
US7045515B2 (en) | 2006-05-16 |
BRPI0206193B1 (pt) | 2016-05-24 |
EP1362855A4 (en) | 2005-02-23 |
CN1492865A (zh) | 2004-04-28 |
HK1060357A1 (en) | 2004-08-06 |
BR0206193A (pt) | 2004-02-03 |
KR100721639B1 (ko) | 2007-05-23 |
CN1273467C (zh) | 2006-09-06 |
DE60222742T2 (de) | 2008-07-17 |
DE60222742D1 (de) | 2007-11-15 |
ATE374769T1 (de) | 2007-10-15 |
MXPA03005073A (es) | 2003-09-05 |
EP1362855B1 (en) | 2007-10-03 |
JPWO2002066464A1 (ja) | 2004-06-17 |
DK1362855T3 (da) | 2008-01-28 |
CA2438961C (en) | 2010-02-16 |
RU2301799C2 (ru) | 2007-06-27 |
RU2003128424A (ru) | 2005-01-27 |
JP4229701B2 (ja) | 2009-02-25 |
KR20030076690A (ko) | 2003-09-26 |
US20040063929A1 (en) | 2004-04-01 |
WO2002066464A1 (en) | 2002-08-29 |
PT1362855E (pt) | 2007-12-04 |
ES2294101T3 (es) | 2008-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI291957B (en) | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same | |
US10577352B2 (en) | Cot modulators and methods of use thereof | |
TW548274B (en) | Dihydropyrimidines having hepatitis B therapeutic efficacy | |
ES2576478T3 (es) | Determinadas amidas sustituidas, procedimiento de preparación y procedimiento de utilización de las mismas | |
JP6063934B2 (ja) | 統合失調症、認識障害及び疼痛などの疾患の治療におけるd−アミノ酸オキシダーゼ(daao)阻害剤としての、5−又は6−置換3−ヒドロキシ−2(1h)−ピリジノン | |
UA63875C2 (en) | Substituted imidazoles, a process for the preparation thereof, a pharmaceutical composition based thereon and a method for treatment | |
CN101316829A (zh) | 具有crth2受体活性的噁二唑衍生物 | |
EP1396487A1 (en) | Phenylpyridine carbonyl piperazine derivative | |
CN1083061A (zh) | 制备芳基哌嗪基-杂环化合物的方法 | |
TW399051B (en) | A novel benzoazine thiazolidinedione derivative and pharmaceutical composition for reducing blood glucose | |
TW420669B (en) | Pyridine type thiazolidines | |
JPH08506354A (ja) | 5−[2−(4−(ベンゾイソチアゾール−3−イル)−ピペラジン−1−イル)エチル−6−クロロ−1,3−ジヒドロ−インドール−2−オンの製造方法及び製造用中間体 | |
CA1172636A (en) | Thiazolidinylalkylene piperazine derivatives | |
CN108419435A (zh) | 用于治疗癌症的化合物和表观遗传学 | |
JP2005517643A5 (zh) | ||
CN1072655C (zh) | 新型杂环氨甲基化合物,其制备方法及含有它们的药物组合物 | |
JP6758374B2 (ja) | Idh2突然変異を標的とする抗腫瘍化合物及びその使用方法 | |
CN102149678A (zh) | 用于治疗癌症的新型邻氨基酰苯胺类 | |
TW450954B (en) | Phenylsulfonamide-phenylethylamines useful as dopamine receptors | |
TW202045516A (zh) | 雙環磺醯胺 | |
JPH02289556A (ja) | オキサゾール化合物 | |
TW593294B (en) | Polycyclic thiazole systems having anorectic activity, processes for their preparation and pharmaceutical composition comprising these compounds | |
CN102046575B (zh) | 阿尔茨海默病治疗药 | |
CN1585772B (zh) | 趋化因子受体拮抗剂及其方法和用途 | |
KR840003250A (ko) | 3-(1h-테트라졸-5-일)-4-(3h)-퀴나졸리논의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |